Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ata Akhtari kohnehshahri"'
Autor:
Mohammad Amin Karimi, Alireza Ghajari, Reza Khademi, Mohammad Hossein Etemadi, Narges Safar Firouz, Behnaz Mohammadvand, Kimia Janeshin, Afra Darvishi, Shafagh Asgarzadeh, Sayedeh-Fatemeh Sadat-Madani, Mohammad Abbasalizadeh, Zahra Jafari Shendi, Ata Akhtari Kohnehshahri, Niloofar Deravi, Seyed Amirhossein Mazhari, Mahsa Aziz, Matin Bidares, Mohaddeseh Belbasi, Mahdyieh Naziri, Hossein Ashkpour Motlagh
Publikováno v:
IBRO Neuroscience Reports, Vol 17, Iss , Pp 207-219 (2024)
Background: Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by dopamine depletion and severe motor impairments. Preladenant, an adenosine A2 receptor antagonist, is an investigational treatment for PD. This systematic r
Externí odkaz:
https://doaj.org/article/9327aa8a9c8b4c3c9183f771774b0db9
Autor:
Narges Norouzkhani, Shaghayegh Afshari, Sayedeh-Fatemeh Sadatmadani, Mohammad Mahdi Mollaqasem, Shakila Mosadeghi, Hani Ghadri, Safa Fazlizade, Keyvan Alizadeh, Pouyan Akbari Javar, Hamidreza Amiri, Elaheh Foroughi, Arina Ansari, Kourosh Mousazadeh, Bozorgmehr Abdullahzadeh Davany, Ata Akhtari kohnehshahri, Alaleh Alizadeh, Parisa Alsadat Dadkhah, Mohadeseh Poudineh
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Aging significantly impacts several age-related neurological problems, such as stroke, brain tumors, oxidative stress, neurodegenerative diseases (Alzheimer’s, Parkinson’s, and dementia), neuroinflammation, and neurotoxicity. Current treatments f
Externí odkaz:
https://doaj.org/article/23e1a6b1c2f547118882acb850986c42
Publikováno v:
Drug Week; 5/31/2024, p869-869, 1p